Home     About SABCS     Media     Event Photos     Past Symposia     Patient Advocates     FAQs     Contact Us

Abstract Information     Registration     Hotel     Support & Exhibits     2015 Overview     Program     Faculty     Travel & Transportation     Satellite Symposia    

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Product Theatre Schedule
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Daily Schedule - Friday, December 12, 2014

Tuesday | Wednesday | Thursday | Friday | Saturday
7:00 am - 5:15 pm Registration - Bridge Hall
7:30 am - 9:00 am

POSTER SESSION 4 & continental breakfast – Halls A-B


Detection and Diagnosis


Circulating Tumor Cells

Circulating Markers






Tumor Cell and Molecular Biology


Microenvironment - Stromal-Epithelial

Oncogenes/Tumor Suppressor Genes

Growth Factors

Micro RNAs

Systems Biology of Breast Cancer












Prognostic and Predictive Factors


Prognostic Factors - Clinical Testing and


  Epidemiology, Risk, and Prevention  

Familial Breast Cancer - Genetic Testing

Familial Breast Cancer - Molecular Genetics

Ethnic/Racial Aspects





HER2-Targeted Therapy

Patient Resources

Tissue and Data Banks

Clinical Trials Design and Management





9:00 am - 9:30 am



Adjuvant Endocrine Therapy in 2015

Nancy E. Davidson, MD

University of Pittsburgh

Pittsburgh, PA

9:30 am - 11:30 am


Moderator: Richard L. Crownover, MD, PhD, UT Health Science Center, San Antonio, TX

9:30 am

S5-01. The Connecticut experiment: 4 years of screening women with dense breasts with bilateral ultrasound
Weigert JM.  Hospitals of Central Connecticut, New Britain, CT; Mandell and Blau MD's PC, New Britain, CT.

9:45 am

S5-02. Discussant
Jafi A. Lipson
, MD

Stanford University School of Medicine

Stanford, CA

10:00 am

S5-03. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial

Livi L, Meattini I, Marrazzo L, Pallotta S, Simontacchi G, Saieva C, Scotti V, De Luca Cardillo C, Bastiani P, Nori J, Orzalesi L, Bianchi S.  Radiotherapy-Oncology Unit, Florence University Hospital, Florence, Italy; Medical Physics Unit, Florence University Hospital, Florence, Italy; Cancer Research and Prevention Institute, Florence, Italy; S. Maria Annunziata Hospital, Florence, Italy; Senology Diagnostic Unit, Florence University Hospital, Florence, Italy; Breast Surgery Unit, Florence University Hospital, Florence, Italy; Division of Pathological Anatomy, Florence University Hospital, Florence, Italy.

10:15 am

S5-04. A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation
Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Slodkowska E, Anderson JM, Jamshidian F, Cherbavaz DB, Shak S, Paszat L.  Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Genomic Health, Inc., Redwood City, CA; University of California, San Francisco, San Francisco, CA; London Health Sciences Centre, London, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Henderson General Hospital, Hamilton, ON, Canada; Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada; Northern Ontario School of Medicine, Thunder Bay, ON, Canada; Health Sciences North Sudbury, Sudbury, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada.

10:30 am

S5-05.  Defective stalled replication fork repair and predisposition to hereditary breast cancer

Pathania S, Bade S, Le Guillou M, Burke K, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM.  Dana Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Laboratoire Stabilite' Genetique et Oncogenese, Université Paris-Sud, Gustave-Roussy, Villejuif, France; Massachusetts General Hospital, Charlestown, MA; Brigham and Women's Hospital, Boston, MA.

10:45 am

S5-06.  Large-scale identification of cell-specific PARP substrates

Yu Y, Zhang Y.  UT Southwestern Medical Center, Dallas, TX.

11:00 am

S5-07.   A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

Leyland-Jones B, Bondarenko I, Nemsadze G, Smirnov V, Litvin I, Kokhreidze I, Abshilava L, Janjalia M, Li R, Lakshmaiah KC, Samkharadze B, Tarasova O, Mohapatra R, Sparyk Y, Polenkov S, Vladimirov V, Xiu L, Kimelblatt B, Deprince K, Safonov I, Vercammen E, Bowers P.  Avera Cancer Institute, Sioux Falls, SD; Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine; Institute of Clinical Oncology (LTD. K. Madichi Mammological Center), Tbilisi, Georgia; Donetsk Regional Anticancer Center, Donetsk, Ukraine; Dnepropetrovsk regional oncological dispensary, Dnepropetrovsk, Ukraine; Martin D. Abeloff Laboratory Cancer Research Center, Tbilisi, Georgia; Chemotherapy and Immunotherapy Clinic MEDULLA, Tbilisi, Georgia; Tbilisi Cancer Center, Tbilisi, Georgia; St. Luke's Medical Center, Quezon City, Philippines; Kidwai Memorial Institute of Oncology, Bangalore, India; Research Institute of Clinical Medicine, Tbilisi, Georgia; Institute of Medical Radiology, Kharkiv, Ukraine; Apollo Specialty Hospital, Chennai, India; Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, Ukraine; Chernigov Regional oncology center, Chernigov, Ukraine; Pyatigorsk Oncology Dispensary, Pyatigorsk, Russian Federation; Janssen R&D, Raritan, NJ; Janssen R&D, Beerse, Belgium; Janssen R&D, Moscow, Russian Federation; Janssen R&D, High Wycombe, United Kingdom.

11:15 am

S5-08. Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy

Chlebowski RT, Blackburn GL.  Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Beth Isreal Deaconess Hospital, Boston, MA; on behaf of the Women's Intervention Nutrition Study investigators, Torrance, CA.

11:30 am - 12:00 pm

AACR Distinguished Lectureship in Breast Cancer Research - Exhibit Hall D


Genomic Analysis of Inherited Breast and Ovarian Cancer

Mary-Claire King, PhD

University of Washington

Seattle, WA

12:00 pm - 1:00 pm LUNCH AND EXHIBITS
1:00 pm - 2:00 pm


  Moderator: Mothaffar Rimawi, MD, Baylor College of Medicine, Houston, TX



Richard L. Crownover, MD, PhD

UT Health Science Center

San Antonio, TX


Andres Forero, MD

University of Alabama

Birmingham, AL


W. Fraser Symmans, MD

UT MD Anderson Cancer Center

Houston, TX


Prof. Dr. Michael Untch

Helios Hospital Berlin-Buch



Joan Venticinque

Breast Cancer Connections

Palo Alto, CA


Antonio C. Wolff, MD

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD

1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Ballroom B

How Do Mutations Occur in Breast Cancer?

Moderator: Douglas Yee, MD, University of Minnesota, Minneapolis, MN

APOBEC3B-catalyzed mutagenesis in breast cancer

Reuben Harris, PhD

University of Minnesota

Minneapolis, MN


RNA editing and cancer stem cell generation

Catriona Jamieson, MD, PhD

UCSD Moore Cancer Center

La Jolla, CA


2:15 pm - 3:15 pm



Targeting Epigenetics in Breast Cancer

Moderator: Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD

Epigenetic abnormalities in breast cancer

Peter W. Laird, PhD

Van Andel Research Institute

Grand Rapids, MI


Targeting epigenetics in breast cancer: clinical implications

Vered Stearns, MD

Johns Hopkins University School of Medicine

Baltimore, MD

3:15 pm - 5:00 pm


Moderator: Nicholas Turner, PhD, FRCP, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM

3:15 pm

S6-01. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D.  University of California, Division of Hematology-Oncology, Department of Medicine, Los Angeles, CA; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Beijing 307 Hospital of PLA, Beijing, China; Department of Breast Surgery, Cancer Hospital of Fudan University, Shanghai, China; Instituto Nacional de Enfermedades Neoplasicas, Surquillo, Lima, Peru; Instituto do Cåncer do Estado de São Paulo, São Paulo, Brazil; Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China; Ruijin Hospital Shanghai Jiao Tong Univ. School of Medicine, Shanghai, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Medical Oncology, University of Pretoria, Gauteng, South Africa; Department of Internal Medicine, Jiangsu Provincial Tumor Hospital, Nanjing, Jiangsu, China; Sarah Cannon Research Institute, Nashville, TN; Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; International Drug Development Institute, Louvain La Neuve, Belgium; Translational Research in Oncology (TRIO), Paris, France; Translational Research in Oncology (TRIO), Edmonton, Canada; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

3:30 pm

S6-02. TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer
Rimawi MF, Niravath PA, Wang T, Rexer B, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick AC, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK.  Baylor College of Medicine, Houston, TX; Vanderbilt University, Nashville, TN; University of Alabama-Birmingham, Birmingham, AL; Johns Hopkins University, Baltimore, MD; University of Chicago, Chicago, IL; Indiana University, Indianapolis, IN; Dana Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN.

3:45 pm

S6-03.  Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial

Adelson KB, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Villalona MC, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.  Yale Cancer Institute, Yale University School of Medicine, New Haven, CT; Ohio State University, Columbus, OH; Montefiore Medical Center, Bronx, NY; Weill Cornell Medical Center, New York, NY; Cancer Therapy Evaluation Program - National Cancer Institute, Bethesda, MD; North Shore - LIJ Cancer Institute, Lake Success, NY; Washington University School of Medicine, St Louis, MO; Columbia University Medical Center, New York, NY; University Hospitals of Cleveland, Cleveland, OH; Mount Sinai Medical Center--Beth Israel, New York, NY; Cleveland Clinic Taussig cancer Institute, Cleveland, OH; New York University School of Medicine, New York, NY; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Connecticut Health Center, Farmington, CT; Mount Sinai Medical Center - Roosevelt, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

4:00 pm

S6-04. Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II 'FIRST' study
Robertson JFR, Llombart-Cussac A, Feltl D, Dewar J, Jasiówka M, Hewson N, Rukazenkov Y, Ellis MJ. Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham, Derby, Nottingham, United Kingdom; Hospital Arnau de Vilanova, Lérida, Spain; FNsP Ostrava, Radioterapeutická klinika, Ostrava-Poruba, Czech Republic; Department of Oncology, Ninewells Hospital and Medical School, Dundee, United Kingdom; Centrum Onkologii, Instytut im Marii Sklodowskiej-Curie, Kraków, Poland; AstraZeneca, Macclesfield, United Kingdom; Washington University School of Medicine, St Louis, MO

4:15 pm

S6-05.  Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program
Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leewen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Peeters S, Fraser J, Nowaczyk M, Rubio I, Aebi S, Kelly C, Ruddy K, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Van Den Weyngaert D, Bogler O, Goulioti T, Dif N, Messina C, Tryfonidis K, Bogaerts J, Giordano S.  Champalimaud Cancer Center, Breast Unit, Lisbon, Portugal; Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada; University of Edinburgh, Scotland, United Kingdom; Department of Statistics, European Organization for Research and Treatment of Cancer, Brussels, Belgium; Department Pathology, Erasmus Medical Center, Rotterdam, Netherlands; Dutch Breast Cancer Research Group (BOOG), Netherlands; Divisions of human biology and public health sciences, Fred Hutchinson Cancer Research Center; Department of Pathology, University of Washington, Seattle; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Lund University, Lund, Sweden; Department Medical Oncology, University Medical Center, Groningen, Netherlands; Breast Cancer Genomics and Proteomics Lab, Erasmus Medical Center, Rotterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston; Department of Medical Oncology, ZNA Jan Palfijn, Belgium; Departments of Oncology and Radiotherapy, UZ Leuven, Leuven, Belgium; Beatson West of Scotland Center, Glasgow Scotland, United Kingdom; Specialist Hospital St. Wojciech, Gdansk, Poland; Breast Surgical Unit, Hospital Universitario, Vall d'Hebron, Barcelona, Spain; Swiss Group for Clinical Cancer Research (SAAK), Switzerland; All Ireland Cooperative Oncology Research Group (ICORG), Ireland; Mayo Clinic, Department of Oncology, Rochester; Dana Farber Cancer Institute, Boston; Department of Oncology, Vastmanlands Hospital, Sweden; Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium; University of Washington, Seattle; Department of Oncology, Cheltenham General Hospital, United Kingdom; Department of Radiotherapy, ZNA, Middelheim, Belgium; Global Academic Programs, University of Texas, MD Anderson Cancer Center, Houston, TX; Breast International Group, Headquarters, Brussels, Belgium; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Medical Department, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Departments of Health Services Research and Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX.

4:30 pm

S6-06. The genomic landscape of male breast cancers 

Piscuoglio S, Murray M, Ng CKY, Guerini Rocco E, Martelotto LG, Bidard F-C, Eberle CA, Fusco N, Sakr RA, De Mattos-Arruda L, Lim R, Baslan T, Hicks J, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS.  Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; School of Pathology, University of Milan, Milan, Italy; Institut Curie, Paris, France; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

4:45 pm

S6-07. Detrimental effects of sequential compared to concurrent treatment of pertuzumab plus T-DM1 in HER2+ breast cancer cell lines

Korkola JE, Liu M, Liby T, Heiser L, Feiler H, Gray JW.  Oregon Health & Science University, Portland, OR.

5:00 pm - 7:00 pm

POSTER DISCUSSION 5: Targeting the PI3K Pathway- Ballroom A


Todd W. Miller, PhD - Co-Discussant

Dartmouth Medical School

Lebanon, NH


Elizabeth Claire Dees, MSc, MD - Co-Discussant

University of North Carolina at Chapel Hill

Chapel Hill, NC

5:00 pm - 7:00 pm

POSTER DISCUSSION 6: Targeting Hormone Resistance: ER Mutation & Fusion - Ballroom B


Steffi Oesterreich, PhD - Co-Discussant

University of Pittsburgh

Pittsburgh, PA

Sarat Chandarlapaty, MD, PhD - Co-Discussant

Memorial Sloan-Kettering Cancer Center

New York, NY

5:00 pm - 7:00 pm

POSTER SESSION 5 & reception - Hall A-B


Detection and Diagnosis


Molecular, Functional, and Novel Imaging

Diagnostic Pathology

Detection/Diagnosis - Other





Tumor Cell and Molecular Biology


Immunology and Preclinical Immunotherapy

Drug Resistance

DNA Damage and Repair

Cellular Mechanisms

Cell Cycle Regulation







Prognostic and Predictive Factors


Prognostic Factors - Preclinical

Prognostic Factors and Biomarkers - Methods



  Epidemiology, Risk, and Prevention  

Prevention - Preclinical Studies and Model

Prevention - Clinical Trials

Prevention - Behavioral Interventions

Prevention - Nutritional Studies






  Psychosocial, Quality of Life, and Educational Aspects  

Quality of Life - Supportive Care

Palliation and Pain Management

Psychosocial Aspects





Adjuvant Therapy - Targeted

Advanced Therapy - Targeted

Signal Transduction Inhibitors

Adjuvant Therapy - Other






Ongoing Clinical Trials 3



Response Prediction

Prognostic Factors


Case Management








7:30 pm

SABCS Special Satellite Symposium presented by Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) - Ballroom B

Minimal requirements and radiation therapy standards for breast cancer in countries with limited resources





AROME Program


Welcome and Introduction

Adapting means to cancer care in the countries with limited resources

Joseph Gligorov, MD, PHD (President of AROME)

Medical Oncology, Tenon Hospital

Univesity Pierre et Marie Curie. Paris VI

Paris, France


New drugs in in the countries with limited resources: how to overcome disparities?

Hamouda Bousse, MD

Univesristy Hospital A. Mami, Ariana

Tunis, Tunisia


Adapting evidence based radiotherapy to countries with limited resources

Adela Poitevin, MD

Médica Sur

Mexico City, Mexico


Gaps and Disparities:  Bridging the Gap

Fady Geara, MD, PHD

Radiation Oncology

The American University of Beirut Medical Center

Beirut, Lebanon


Radiotherapy Techniques According To Means: Minimal requirements and standards

Nuran Bese, MD

Cerrahpasa Medical School

Istanbul University

Istanbul, Turkey


Radiotherapy Indications According To Means: Standards and Controversies for maximal efficacy

Yazid Belkacemi, MD, PHD

Henri Mondor Breast Center and Radiation Oncology Department

Univesity of Paris East Creteil (UPEC)

Creteil, France


Regional Radiation in Breast Cancer: How to Prevent Toxicities?

Alphonse G. Taghian, MD, PhD

Harvard Medical School

Radiation Oncology and Breast Cancer Research Program

Massachusetts General Hospital

Boston, MA


Discussion with panel

spacer spacer spacer
Tuesday | Wednesday | Thursday | Saturday
Home | About SABCS | Media | Event Photos | Past Symposia | Patient Advocates | FAQs | Contact Us
Abstract Information | Registration | Hotel | Support & Exhibits | 2015 Overview | Program | Faculty | Travel & Transportation | Satellite Symposia

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright 2015 SABCS. All rights reserved. - Privacy Policy